Cullgen
Astellas and Cullgen enter into $1.9bn strategic collaboration to progress protein degraders
June 15, 2023Research and Development Astellas, Cullgen, Oncology, protein degraders
Japanese pharmaceutical company Astellas and US-based clinical-stage biopharmaceutical company Cullgen have announced that they have entered into a strategic research …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
